GC Cell (GC셀) announced on the 5th that it will present the results of a Phase 1a clinical study of its CD5-targeted allogeneic CAR-NK (chimeric antigen receptor natural killer cell) cell therapy “GCC2005” at the 68th American Society of Hematology (ASH 2026) Annual Meeting, to be held in New Orleans, Louisiana, United States, from December 12 to 15.
CD5 (Cluster of Differentiation 5) is a type of protein marker present on the surface of immune cells in the human body. Under normal conditions, it functions as a safety mechanism to prevent T-cell overactivation, but when genetic mutations and other factors cause transformation into cancer cells, it leads to T‑cell lineage malignant hematologic cancers. Because these cancer cells originate from T cells, the CD5 protein remains expressed. CAR-NK and CAR-T therapies are designed to target CD5 and induce apoptosis of the cancer cells.
According to GC Cell, the abstract to be presented contains the results of a Phase 1a trial involving 18 patients with relapsed or refractory CD5-positive NK and T-cell malignancies. It includes overall safety and tolerability data as well as an initial efficacy assessment. The Phase 1a trial was conducted using a 3+3 dose-escalation design.
GC Cell reported that in the safety assessment, no dose-limiting toxicities (DLTs) were observed up to the highest dose level, and the maximum tolerated dose (MTD) was not reached. All cases of cytokine release syndrome (CRS) were reported as mild. No treatment-related serious adverse events were reported, and there were no major safety issues such as immune effector cell–associated neurotoxicity syndrome (ICANS), graft-versus-host disease (GvHD), febrile neutropenia, or severe and opportunistic infections.
In particular, the trial enrolled patients with T-cell lymphoma who had relapsed after multiple lines of anticancer therapy or had been unresponsive to treatment. Subtypes included peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL).
In the initial efficacy evaluation, antitumor activity was observed across multiple dose levels. Some patients showed favorable initial treatment responses, including durable complete responses (CRs), in which cancer cells became undetectable. GC Cell emphasized that these results demonstrate the therapeutic potential of GCC2005 in the T-cell lymphoma patient population.
GCC2005 is a core pipeline asset of GC Cell and is being developed as a first-in-class new drug candidate for the treatment of refractory T-cell lymphoma. It is designed to co-express CAR (chimeric antigen receptor) and interleukin-15 (IL-15) to enhance antitumor activity and in vivo persistence. IL-15 is an essential cytokine protein that activates and supports the survival of immune cells, and is sometimes referred to as a “nutrient” for immune cells. It plays a key role in the generation, survival, and maintenance of cytotoxicity in NK cells and T cells. GC Cell explained that GCC2005 is being developed in an off-the-shelf format, manufactured in advance and stored so that it can be administered immediately when needed.
The company has also initiated dosing in a Phase 1b trial. The first patient was dosed last month. The Phase 1b study is designed to optimize regimen and dosage and to conduct exploratory dose expansion. Based on this, the company aims to determine the recommended Phase 2 dose (RP2D) to be used in a Phase 2 trial.
Professor Kim Won-Seog of the Division of Hematology-Oncology at Samsung Medical Center, the principal investigator of the study, stated, “This Phase 1a trial was a safety-focused dose-escalation study that included patients with various T-cell lymphoma subtypes and a wide range of CD5 expression levels, and it demonstrated favorable safety, tolerability, and initial antitumor activity signals. Given that some patients achieved long-lasting complete responses, there is a need for subsequent trials to more precisely evaluate the optimal dose and treatment responses.”
Won Sung-yong, CEO of GC Cell, said, “Following last year’s interim data, we are presenting the full Phase 1a dataset of GCC2005 at ASH this year. Based on the confirmed safety and early clinical results, we will steadily advance the ongoing Phase 1b trial to establish the optimal dose and accelerate our efforts to transition to global clinical development in the future.”
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News